FDA Drug · D-0552-2026

Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02

Class III · Ongoing

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Affected lots / codes — check yours against thisLot, expiry: Lot 3LC26029A, exp Feb-2029; Lot 3LC26031A, exp Mar-2029

Recalling firm: Eugia US LLC, East Windsor, NJ
Classification: Class III (unlikely to cause harm)
Status: Ongoing
Quantity: 168,300 vials
Distribution: US Nationwide.
Recall initiated: May 18, 2026
Classified: May 29, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0552-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →